Imago BioSciences to Participate in Upcoming Investor Conferences

South San Francisco, Calif. – Feb. 9, 2021 – Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing innovative treatments for myeloid diseases, today announced that executive leadership will be participating in the following upcoming investor conferences:

  • SVB Leerink 10th Annual Global Healthcare Conference
    Date: Feb. 23, 2021
  • Cowen 41st Annual Healthcare Conference
    Date: March 1, 2021

About Imago BioSciences

Imago BioSciences is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for the treatment of hematologic disorders. Imago has developed a series of compounds that inhibit LSD1, an epigenetic enzyme critical for cancer stem cell function and blood cell differentiation. The company is advancing the clinical development of its first LSD1 inhibitor, bomedemstat, for the treatment of myeloid neoplasms. Imago is backed by leading private, public and strategic investors including a fund managed by Blackstone Life Sciences, Frazier Healthcare Partners, Omega Funds, Farallon Capital Management, L.L.C., funds and accounts advised by T. Rowe Price Associates, Inc., and funds and accounts managed by Blackrock Advisors, LLC. The company is based in South San Francisco, California. To learn more, visit www.imagobio.com, www.myelofibrosisclinicalstudy.com, www.etclinicalstudy.com and follow us on Twitter @ImagoBioRx, Facebook and LinkedIn.

Contacts:
Media Contact:
Steve Kunszabo
Canale Communications
steve.kunszabo@canalecomm.com

Investor Contact:
Matthew Plunkett, PhD,
Chief Financial Officer, Imago Biosciences
matthew.plunkett@imagobio.com